BidaskClub downgraded shares of Dynavax Technologies (NASDAQ:DVAX) from a sell rating to a strong sell rating in a research note issued to investors on Friday morning.
DVAX has been the topic of a number of other research reports. Cantor Fitzgerald boosted their target price on Dynavax Technologies from $24.00 to $25.00 and gave the stock an overweight rating in a research note on Thursday, November 9th. Zacks Investment Research downgraded Dynavax Technologies from a hold rating to a sell rating in a research note on Wednesday, January 10th. ValuEngine downgraded Dynavax Technologies from a hold rating to a sell rating in a research note on Friday, December 1st. Cowen restated a buy rating and issued a $30.00 target price on shares of Dynavax Technologies in a research note on Friday, November 3rd. Finally, Royal Bank of Canada reaffirmed an outperform rating and issued a $28.00 price target (up previously from $26.00) on shares of Dynavax Technologies in a report on Monday, September 25th. Three investment analysts have rated the stock with a sell rating and five have given a buy rating to the stock. Dynavax Technologies presently has a consensus rating of Hold and a consensus target price of $25.17.
Shares of Dynavax Technologies (DVAX) traded up $0.23 during midday trading on Friday, hitting $15.65. The stock had a trading volume of 1,019,000 shares, compared to its average volume of 1,683,554. Dynavax Technologies has a 12-month low of $3.70 and a 12-month high of $24.45. The stock has a market cap of $1,010.00, a P/E ratio of -7.98 and a beta of 1.31.
Dynavax Technologies (NASDAQ:DVAX) last announced its earnings results on Friday, November 3rd. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.15. Dynavax Technologies had a negative return on equity of 65.97% and a negative net margin of 1,177.60%. The firm had revenue of $0.05 million for the quarter, compared to the consensus estimate of $0.28 million. During the same quarter in the previous year, the business earned ($0.90) EPS. The company’s revenue was down 68.8% compared to the same quarter last year. research analysts anticipate that Dynavax Technologies will post -1.72 earnings per share for the current year.
In related news, insider Robert Coffman sold 7,500 shares of Dynavax Technologies stock in a transaction that occurred on Wednesday, December 13th. The shares were sold at an average price of $18.90, for a total value of $141,750.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, VP David Louis Johnson sold 3,092 shares of Dynavax Technologies stock in a transaction that occurred on Thursday, January 4th. The stock was sold at an average price of $18.60, for a total transaction of $57,511.20. Following the completion of the sale, the vice president now directly owns 7,780 shares in the company, valued at approximately $144,708. The disclosure for this sale can be found here. Insiders own 2.90% of the company’s stock.
Large investors have recently bought and sold shares of the stock. Cubist Systematic Strategies LLC raised its holdings in shares of Dynavax Technologies by 54.5% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 10,493 shares of the biopharmaceutical company’s stock worth $101,000 after purchasing an additional 3,700 shares during the period. Legal & General Group Plc raised its holdings in shares of Dynavax Technologies by 18.5% in the 2nd quarter. Legal & General Group Plc now owns 12,501 shares of the biopharmaceutical company’s stock worth $121,000 after purchasing an additional 1,950 shares during the period. Wall Street Access Asset Management LLC bought a new stake in shares of Dynavax Technologies in the 2nd quarter worth approximately $124,000. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Dynavax Technologies by 474.2% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,120 shares of the biopharmaceutical company’s stock worth $153,000 after purchasing an additional 5,880 shares during the period. Finally, Family Management Corp raised its holdings in Dynavax Technologies by 72.7% during the 2nd quarter. Family Management Corp now owns 19,000 shares of the biopharmaceutical company’s stock valued at $183,000 after acquiring an additional 8,000 shares during the period. 70.54% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY WARNING: This piece was reported by TrueBlueTribune and is owned by of TrueBlueTribune. If you are reading this piece on another publication, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.truebluetribune.com/2018/01/22/dynavax-technologies-dvax-cut-to-strong-sell-at-bidaskclub.html.
Dynavax Technologies Company Profile
Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.